Product logins

Find logins to all Clarivate products below.


Dee Chaudhary

Director, Consulting

With more than 25 years in life sciences and a passion for patients, Dee Chaudhary is a Director with Clarivate’s Commercial Strategy Consulting practice.  Her work in consulting, and within the biopharmaceutical industry has primarily focused on HUB/patient services, launch readiness, CMS policy impact, customer experience and market access strategy in the hematology and oncology space.

Dee has extensive professional experience with 340B pricing, reimbursement strategy, product positioning and value propositions for oral and infusible agents.  She has led HUB migrations, benchmarking engagements, customer satisfaction projects, omni-channel projects, product differentiation, pricing and positioning efforts, and payer landscape analysis.  Furthermore, Dee has an in-depth understanding of the hematology and oncology market landscape, targeted and cellular therapies, and has a strong interest and experience in other therapeutic areas including cardiology, neuroscience, med tech immunotherapy, and using technology to advance health and access. She has been invited to presented at Asembia, ISPOR and other clinical meetings, and has authored multiple trainings and white papers.

Prior to joining Clarivate, Dee held a variety roles at small and large biopharmaceutical organizations and consulting firms, including National Director of Market Access, Reimbursement and Trade, Senior Director of Customer Experience, and Assistant Director of Reimbursement Consulting. Dee holds a BA from Gustavus Adolphus College in History, and an MBA in Healthcare Administration.


arrow_forward
Get in touch with Dee

Latest news

News July 29, 2026
Clarivate Appoints Michael Easton as Chief Financial Officer

Experienced Clarivate leader brings more than 25 years of financial and operational expertise ​LONDON, July 29, 2026: Clarivate Plc (NYSE: CLVT) (“Clarivate” or the “Company”), a leading global provider of transformative intelligence, today…

News July 29, 2026
Clarivate Reports Second Quarter 2026 Results

— Delivers continued progress on strategic and financial priorities through Value Creation Plan — — Sharpens focus and enhances financial profile with previously announced Life Sciences & Healthcare segment divestiture…

News July 20, 2026
Clarivate RiskMark Wins 2026 CODiE Award for Best AI Tool for Lawyers

Prestigious awards program recognizes innovative AI technology transforming trademark risk assessment for legal professionals London, U.K. July, 20, 2026. Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today…

Related resources

Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval
Blog June 24, 2026
Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval
ADC Biopharma Biotech Bispecific antibodies BsAb Clinical trials Development Oncology Pharma R&D Regulatory Research
Using AI-powered translational safety intelligence to anticipate drug safety issues earlier Using AI-powered translational safety intelligence to anticipate drug safety issues earlier
Blog June 22, 2026
Using AI-powered translational safety intelligence to anticipate drug safety issues earlier
Biopharma Biotech Clinical trials CMC Development R&D Real-World Data Regulatory Research Safety
Three uncomfortable truths about cell and gene therapy in regulatory affairs Three uncomfortable truths about cell and gene therapy in regulatory affairs
Blog May 28, 2026
Three uncomfortable truths about cell and gene therapy in regulatory affairs
Consulting Resource Center Regulatory
How the Inflation Reduction Act could impact access to more convenient therapeutics How the Inflation Reduction Act could impact access to more convenient therapeutics
Blog February 17, 2026
How the Inflation Reduction Act could impact access to more convenient therapeutics
Biopharma Biotech Commercialization Consulting Resource Center FDA HMO Insurance Launch Managed care Market Access North America Payer Pharma pricing Route of administration U.S.